{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T07:22:04Z","timestamp":1780989724208,"version":"3.54.1"},"reference-count":15,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,28]],"date-time":"2017-10-28T00:00:00Z","timestamp":1509148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological Sciences"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.jphs.2017.10.006","type":"journal-article","created":{"date-parts":[[2017,10,28]],"date-time":"2017-10-28T22:46:57Z","timestamp":1509230817000},"page":"220-223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Effect of a SGLT2 inhibitor on the systemic and intrarenal renin\u2013angiotensin system in subtotally nephrectomized rats"],"prefix":"10.1016","volume":"137","author":[{"given":"Lei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chizuko","family":"Kitabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Kobara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Masaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Hitomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Kobori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jphs.2017.10.006_bib1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1681\/ASN.2010030246","article-title":"SGLT2 mediates glucose reabsorption in the early proximal tubule","volume":"22","author":"Vallon","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"22","key":"10.1016\/j.jphs.2017.10.006_bib2","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.jphs.2017.10.006_bib3","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.jphs.2017.10.006_bib4","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.clinthera.2015.10.025","article-title":"Influence of renal function on the 52-week efficacy and safety of the sodium glucose cotransporter 2 inhibitor luseogliflozin in Japanese patients with type 2 diabetes mellitus","volume":"38","author":"Haneda","year":"2016","journal-title":"Clin Ther"},{"issue":"5","key":"10.1016\/j.jphs.2017.10.006_bib5","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/HJH.0000000000000871","article-title":"Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome","volume":"34","author":"Rahman","year":"2016","journal-title":"J\u00a0Hypertens"},{"issue":"6","key":"10.1016\/j.jphs.2017.10.006_bib6","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/hr.2016.2","article-title":"A\u00a0sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats","volume":"39","author":"Takeshige","year":"2016","journal-title":"Hypertens Res"},{"issue":"5","key":"10.1016\/j.jphs.2017.10.006_bib7","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/dom.12090","article-title":"Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease","volume":"15","author":"Yale","year":"2013","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.jphs.2017.10.006_bib8","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/ki.2014.246","article-title":"Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes","volume":"86","author":"Cherney","year":"2014","journal-title":"Kidney Int"},{"issue":"11","key":"10.1016\/j.jphs.2017.10.006_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17111800","article-title":"Urinary angiotensinogen could Be a prognostic marker of the renoprotection of olmesartan in metabolic syndrome patients","volume":"17","author":"Mizushige","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.jphs.2017.10.006_bib10","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1124\/pr.59.3.3","article-title":"The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease","volume":"59","author":"Kobori","year":"2007","journal-title":"Pharmacol Rev"},{"issue":"11","key":"10.1016\/j.jphs.2017.10.006_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165703","article-title":"Effect of sodium-glucose Co-Transporter 2 inhibitor, dapagliflozin, on renal renin-angiotensin system in an animal model of type 2 diabetes","volume":"11","author":"Shin","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jphs.2017.10.006_bib12","article-title":"Sodium-glucose linked Cotransporter-2 inhibition does not attenuate disease progression in the rat remnant kidney model of chronic kidney disease","volume":"11","author":"Zhang","year":"2016","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jphs.2017.10.006_bib13","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jphs.2016.10.006","article-title":"Changes in glucose-induced plasma active glucagon-like peptide-1 levels by co-administration of sodium-glucose cotransporter inhibitors with dipeptidyl peptidase-4 inhibitors in rodents","volume":"132","author":"Oguma","year":"2016","journal-title":"J\u00a0Pharmacol Sci"},{"issue":"2","key":"10.1016\/j.jphs.2017.10.006_bib14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1254\/jphs.13045FP","article-title":"Angiotensin-converting enzyme inhibitor does not suppress renal angiotensin II levels in angiotensin I-infused rats","volume":"122","author":"Ohnishi","year":"2013","journal-title":"J\u00a0Pharmacol Sci"},{"key":"10.1016\/j.jphs.2017.10.006_bib15","doi-asserted-by":"crossref","first-page":"26428","DOI":"10.1038\/srep26428","article-title":"Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db\/db mice","volume":"6","author":"Gallo","year":"2016","journal-title":"Sci Rep"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861317301755?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861317301755?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T12:01:39Z","timestamp":1589803299000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347861317301755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S1347861317301755"],"URL":"https:\/\/doi.org\/10.1016\/j.jphs.2017.10.006","relation":{},"ISSN":["1347-8613"],"issn-type":[{"value":"1347-8613","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of a SGLT2 inhibitor on the systemic and intrarenal renin\u2013angiotensin system in subtotally nephrectomized rats","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jphs.2017.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.","name":"copyright","label":"Copyright"}]}}